Alterations of cell cycle control proteins SHP-1/2, p16, CDK4 and cyclin D1 in radioresistant nasopharyngeal carcinoma cells

Molecular Medicine Reports

Volumn 10, Issue 4, 2014, Pages 1709-1716

  Peng, Gang ^a   Cao, Ru Bo ^a   Li, Yue Hua ^a   Zou, Zhen Wei ^a   Huang, Jing ^a   Ding, Qian ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cell cycle; Cyclin D1; Nasopharyngeal carcinoma; p16; Radiosensitivity; SHP 1

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; PTPN11 PROTEIN, HUMAN; PTPN6 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANTAGONISTS AND INHIBITORS; G1 PHASE CELL CYCLE CHECKPOINT; GAMMA RADIATION; GENETICS; HUMAN; METABOLISM; NASOPHARYNX TUMOR; PATHOLOGY; RADIATION DOSE; RADIATION RESPONSE; RNA INTERFERENCE; TUMOR CELL LINE; UPREGULATION;

CELL LINE, TUMOR; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; G1 PHASE CELL CYCLE CHECKPOINTS; GAMMA RAYS; HUMANS; NASOPHARYNGEAL NEOPLASMS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RADIATION TOLERANCE; RNA INTERFERENCE; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84924219895     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2463     Document Type: Article

References (47)

1. Tulalamba W and Janvilisri T: Nasopharyngeal carcinoma signaling pathway: an update on molecular biomarkers. Int J Cell Biol 2012: 594681, 2012.
2. Chang ET and Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15: 1765-1777, 2006. (Pubitemid 44664247)
3. Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, Zee BC, Law SC, Teo PM, Tung SY, Kwong DL and Lau WH: Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61: 1107-1116, 2005. (Pubitemid 40340904)
4. Lee AW, Poon YF, Foo W, Law SC, Cheung FK, Chan DK, Tung SY, Thaw M and Ho JH: Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 23: 261-270, 1992.
5. Langendijk JA, Leemans CR, Buter J, Berkhof J and Slotman BJ: The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 22: 4604-4612, 2004. (Pubitemid 41185128)
6. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS and Wang WY: Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21: 631-637, 2003.
7. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Yang E, Lee KM, Fong KW, Tan HS, Lee KS, Loong S, Sethi V, Chua EJ and Machin D: Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23: 6730-6738, 2005. (Pubitemid 46190268)
8. Feng XP, Yi H, Li MY, Li XH, Yi B, Zhang PF, Li C, Peng F, Tang CE, Li JL, Chen ZC and Xiao ZQ: Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res 70: 3450-3462, 2010.
9. Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, Hagan MP, Grant S and Schmidt-Ullrich R: Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 159: 283-300, 2003. (Pubitemid 36314943)
10. Sung FL, Hui EP, Tao Q, Li H, Tsui NB, Dennis Lo YM, Ma BB, To KF, Harris AL and Chan AT: Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. Cancer Lett 253: 74-88, 2007. (Pubitemid 46881199)
11. Morrison JA, Gulley ML, Pathmanathan R and Raab-Traub N: Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res 64: 5251-5260, 2004. (Pubitemid 39006545)
12. Li L, Tao Q, Jin H, van Hasselt A, Poon FF, Wang X, Zeng MS, Jia WH, Zeng YX, Chan AT and Cao Y: The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin Cancer Res 16: 2949-2958, 2010.
13. Zeng ZY, Zhou YH, Zhang WL, Xiong W, Fan SQ, Li XL, Luo XM, Wu MH, Yang YX, Huang C, Cao L, Tang K, Qian J, Shen SR and Li GY: Gene expression profiling of nasopharyngeal carcinoma reveals the abnormally regulated Wnt signaling pathway. Hum Pathol 38: 120-133, 2007. (Pubitemid 44880208)
14. Oka T, Yoshino T, Hayashi K, Ohara N, Nakanishi T, Yamaai Y, Hiraki A, Sogawa CA, Kondo E, Teramoto N, Takahashi K, Tsuchiyama J and Akagi T: Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray. Am J Pathol 159: 1495-1505, 2001. (Pubitemid 32947978)
15. Neel BG, Gu H and Pao L: The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28: 284-293, 2003. (Pubitemid 36776291)
16. Mittal Y, Pavlova Y, Garcia-Marcos M and Ghosh P: Src homology domain 2-containing protein-tyrosine phosphatase-1 (SHP-1) binds and dephosphorylates G(alpha)-interacting, vesicle-associated protein (GIV)/Girdin and attenuates the GIV-phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway. J Biol Chem 286: 32404-32415, 2011.
17. Beyaert R: SHP works a double shift to control TLR signaling. Nat Immunol 12: 725-727, 2011.
18. Prasad S, Pandey MK, Yadav VR and Aggarwal BB: Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis. Cancer Prev Res (Phila) 4: 1084-1094, 2011.
19. López-Ruiz P, Rodriguez-Ubreva J, Cariaga AE, Cortes MA and Colás B: SHP-1 in cell-cycle regulation. Anticancer Agents Med Chem 11: 89-98, 2011.
20. Rodríguez-Ubreva FJ, Cariaga-Martinez AE, Cortés MA, Romero-De Pablos M, Ropero S, López-Ruiz P and Colás B: Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery. Oncogene 29: 345-355, 2010.
21. López-Ruiz P, Rodriguez-Ubreva J, Cariaga AE, Cortes MA and Colás B: SHP-1 in cell-cycle regulation. Anticancer Agents Med Chem 11: 89-98, 2011.
22. Yu Z, Maoui M, Zhao ZJ, Li Y and Shen SH: SHP-1 dephosphorylates 3BP2 and potentially downregulates 3BP2-mediated T cell antigen receptor signaling. FEBS J 273: 2195-2205, 2006.
23. Zhang J and Shen B: SHP limits TLR signaling, an inducible transcriptional corepressor. Cell Mol Immunol 8: 445-446, 2011.
24. Iype T, Sankarshanan M, Mauldin IS, Mullins DW and Lorenz U: The protein tyrosine phosphatase SHP-1 modulates the suppressive activity of regulatory T cells. J Immunol 185: 6115-6127, 2010.
25. Biskup C, Böhmer A, Pusch R, Kelbauskas L, Gorshokov A, Majoul I, Lindenau J, Benndorf K and Böhmer FD: Visualization of SHP-1-target interaction. J Cell Sci 117: 5165-5178, 2004. (Pubitemid 39517531)
26. Zhu Z, Oh SY, Cho YS, Zhang L, Kim YK and Zheng T: Tyrosine phosphatase SHP-1 in allergic and anaphylactic inflammation. Immunol Res 47: 3-13, 2010.
27. Seo DW, Li H, Qu CK, Oh J, Kim YS, Diaz T, Wei B, Han JW and Stetler-Stevenson WG: Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J Biol Chem 281: 3711-3721, 2006. (Pubitemid 43845989)
28. Yip SS, Crew AJ, Gee JM, Hui R, Blamey RW, Robertson JF, Nicholson RI, Sutherland RL and Daly RJ: Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. Int J Cancer 88: 363-368, 2000.
29. Ketroussi F, Giuliani M, Bahri R, Azzarone B, Charpentier B and Durrbach A: Lymphocyte cell-cycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway. PLoS One 6: e22776, 2011.
30. Yuan L, Yu WM and Qu CK: DNA damage-induced G2/M checkpoint in SV40 large T antigen-immortalized embryonic fibroblast cells requires SHP-2 tyrosine phosphatase. J Biol Chem 278: 42812-42820, 2003. (Pubitemid 37345891)
31. Yuan L, Yu WM, Yuan Z, Haudenschild CC and Qu CK: Role of SHP-2 tyrosine phosphatase in the DNA damage-induced cell death response. J Biol Chem 278: 15208-15216, 2003. (Pubitemid 36799856)
32. Jiang J, Jin MS, Kong F, Wang YP, Jia ZF, Cao DH, Ma HX, Suo J and Cao XY: Increased expression of tyrosine phosphatase SHP-2 in Helicobacter pylori-infected gastric cancer. World J Gastroenterol 19: 575-580, 2013.
33. Meng F, Zhao X and Zhang S: Expression and significance of SHP-2 in human papillomavirus infected cervical cancer. J Huazhong Univ Sci Technolog Med Sci 32: 247-251, 2012.
34. Hall M and Peters G: Genetic alterations of cyclins, cyclin-dependent kinases and Cdk inhibitors in human cancer. Adv Cancer Res 68: 67-108, 1996. (Pubitemid 26099813)
35. Hwang CF, Cho CL, Huang CC, Wang JS, Shih YL, Su CY and Chang HW: Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy. Ann Oncol 13: 1246-1251, 2002.
36. Gulley ML, Nicholls JM, Schneider BG, Amin MB, Ro JY and Geradts J: Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. Am J Pathol 152: 865-869, 1998. (Pubitemid 28173346)
37. Pearce AG, Segura TM, Rintala AC, Rintala-Maki ND and Lee H: The generation and characterization of a radiation-resistant model system to study radioresistance in human breast cancer cells. Radiat Res 156: 739-750, 2001. (Pubitemid 34024269)
38. Hall EJ and Giaccia A (eds): Radiobiology for the Radiologist. 7th edition. Section I, Chapter 3: Cell survival curves. Lippincott Williams & Wilkins, New York, 2011.
39. Larsen JK, Landberg G and Roos G: Detection of proliferating cell nuclear antigen. Methods Cell Biol 63: 419-431, 2001.
40. Shimura T: Acquired radioresistance of cancer and the AKT/GSK3β/cyclin D1 overexpression cycle. J Radiat Res 52: 539-544, 2011.
41. Deorukhkar A and Krishnan S: Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol 80: 1904-1914, 2010.
42. Brizel DM, Sibley GS, Prosnitz LR, Scher RL and Dewhirst MW: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38: 285-289, 1997. (Pubitemid 27318643)
43. Feng Z, Xu S, Liu M, Zeng YX and Kang T: Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo. Cancer Lett 297: 190-197, 2010.
44. Li AA, Ng E, Shi W, Lee A, Chia M, Liu TJ, Huang D, O'Sullivan B, Gullane P and Liu FF: Potential efficacy of p16 gene therapy for EBV-positive nasopharyngeal carcinoma. Int J Cancer 110: 452-458, 2004. (Pubitemid 38649900)
45. Gupta S and Ahmed MM: A global perspective of radiation-induced signal transduction pathways in cancer therapeutics. Indian J Exp Biol 42:1153-1176, 2004. (Pubitemid 39623423)
46. Storozhuk Y, Sanli T, Hopmans SN, Schultz C, Farrell T, Cutz JC, Steinberg GR, Wright J, Singh G and Tsakiridis T: Chronic modulation of AMP-Kinase, Akt and mTOR pathways by ionizing radiation in human lung cancer xenografts. Radiat Oncol 7: 71, 2012.
47. Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S and Dent P: Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 6: 789-801, 2007. (Pubitemid 46554549)